Difelikefalin acetate

Difelikefalin acetate, also known as CR845, is a synthetic peptide and selective kappa opioid receptor (KOR) agonist that has garnered significant attention in the field of biomedical research. Characterized by its high specificity for peripheral KORs and minimal central nervous system penetration, this compound offers a valuable tool for investigating kappa opioid signaling pathways without eliciting the typical central side effects associated with many opioid compounds. Its unique structure, combining a peptide backbone with an acetate salt form, ensures enhanced stability and solubility, which are critical attributes for reliable in vitro and in vivo experimentation. Researchers have leveraged its pharmacological profile to dissect the nuanced roles of peripheral opioid receptors in various physiological and pathological processes, making it a preferred choice for mechanistic studies and drug discovery initiatives.

Pain Pathway Research: Difelikefalin acetate serves as a robust investigative agent for elucidating the mechanisms of peripheral pain modulation. By selectively activating peripheral kappa opioid receptors, it enables the study of pain transmission and modulation outside the central nervous system. Researchers utilize it to delineate the specific contributions of peripheral KORs in nociceptive signaling, which is essential for understanding pain at the molecular and cellular levels. Its ability to provide targeted receptor activation without significant blood-brain barrier penetration allows for the isolation of peripheral effects, offering clarity in preclinical pain models and supporting the identification of novel analgesic targets.

Itch and Pruritus Mechanism Studies: In dermatological and neurobiological research, CR845 is frequently employed to investigate the molecular underpinnings of pruritus and itch signaling. Studies have demonstrated that peripheral kappa opioid receptor activation by this peptide can modulate itch responses, making it an indispensable tool for dissecting the pathways involved in chronic and acute pruritic conditions. Researchers use it to explore the interactions between sensory neurons and immune mediators, advancing the understanding of how peripheral opioid systems influence itch sensation and paving the way for the development of targeted anti-pruritic strategies.

Renal and Inflammatory Condition Models: Difelikefalin acetate is utilized in experimental models to examine its effects on inflammation and renal function. Its peripheral selectivity allows researchers to assess the modulation of inflammatory mediators and cytokine release in various tissue types, including the kidneys. By employing this compound in both in vitro and in vivo settings, scientists can investigate the impact of peripheral KOR activation on renal inflammation, immune cell recruitment, and tissue injury, contributing to the broader understanding of opioid receptor roles in organ-specific pathophysiology.

Drug Discovery and Pharmacological Profiling: CR845 is a valuable reference compound in the screening and characterization of new kappa opioid receptor modulators. Its well-defined pharmacological properties provide a benchmark for evaluating the efficacy, selectivity, and safety profiles of novel KOR-targeted molecules. High-throughput screening platforms and receptor binding assays often incorporate it to validate assay sensitivity and specificity, thereby facilitating the identification and optimization of next-generation therapeutics aimed at peripheral opioid pathways.

Signal Transduction and Receptor Dynamics: Researchers leverage difelikefalin acetate to probe the intricate signaling cascades downstream of kappa opioid receptor activation. By employing advanced cell-based assays and molecular biology techniques, scientists can dissect the G protein-coupled receptor signaling events, receptor desensitization, internalization, and cross-talk with other cellular pathways. These studies are instrumental in unraveling the complexities of opioid receptor pharmacology, informing the rational design of compounds with tailored signaling profiles and reduced adverse effects.

In summary, difelikefalin acetate stands as a versatile and scientifically significant tool in the exploration of peripheral kappa opioid receptor functions. Its applications span pain and pruritus research, inflammation and renal studies, pharmacological screening, and detailed investigations into receptor-mediated signaling events. By enabling targeted and selective interrogation of peripheral opioid mechanisms, this compound continues to drive innovation and discovery across multiple domains of biomedical research.

1. C-peptide and its C-terminal fragments improve erythrocyte deformability in type 1 diabetes patients

2. Spatiotemporal delivery of nanoformulated liraglutide for cardiac regeneration after myocardial infarction

3. Genetic, cellular, and structural characterization of the membrane potential-dependent cell-penetrating peptide translocation pore

4. GLP-1, exendin-4 and C-peptide regulate pancreatic islet microcirculation, insulin secretion and glucose tolerance in rats

5. The effect of sex on immune responses to a homocitrullinated peptide in the DR4-transgenic mouse model of Rheumatoid Arthritis